Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
ZymoGenetics
Study ID
NCT00347971
Phase
PHASE1
Status
Completed

Conditions

  • Lymphoma, Non-Hodgkin

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).

Key Dates

First listed
Jul 4, 2006
Start date
Jun 30, 2006
Status verified
Sep 2008
Primary completion
Apr 30, 2008
Completion
Apr 30, 2008

Study Design

Enrollment
23 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Incidence and severity of adverse events through 1 month after completing treatment [ Time Frame: During treatment and through 1 month after completing treatment ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, Los AngelesLos AngelesCalifornia90095-

Find similar trials in Los Angeles, CA

By research site
University of California, Los Angeles· Los Angeles, CA

Related Studies